299. 嚢胞性線維症
[臨床試験数:1,592,薬物数:1,539(DrugBank:255),標的遺伝子数:81,標的パスウェイ数:162

Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02518672
(ClinicalTrials.gov)
October 20153/8/2015Pro-resolving Effect of MAG-DHA in Cystic Fibrosis (PREMDIC)Role of DHA Monoglyceride (MAG-DHA) in the Resolution of Pulmonary Inflammation of Patients With Cystic Fibrosis.Cystic FibrosisDietary Supplement: MAG-DHA;Dietary Supplement: PlaceboSCF PharmaCentre de recherche du Centre hospitalier universitaire de Sherbrooke;Solutex (Spain)Terminated18 YearsN/AAll11Phase 2Canada
2NCT02128984
(ClinicalTrials.gov)
January 201228/3/2014Clinical Study With an Enteral Formula With Symbiotic and DHA for Malnourished ChildrenClinical Study With an Enteral Formula With Symbiotic and DHA for Malnourished ChildrenCystic Fibrosis;Failure to Thrive;MalnutritionDietary Supplement: Symbiotic Formula with DHA and antioxidants;Dietary Supplement: Standard FormulaLaboratorios OrdesaQuantum Experimental;Peruvian Clinical ResearchCompleted1 YearN/AAll109N/APeru;Spain
3EUCTR2010-020516-11-IT
(EUCTR)
16/09/201028/09/2010EXPERIMENTAL STUDY, RANDOMIZED, OPEN LABEL, TO EVALUATE THE EFFECT OF DOCOSAHEXAENOIC ACID (DHA) SUPPLEMENTATION VERSUS 5-METHYLTETHRAHYDROFOLATE + B12 VITAMIN AND DHA, IN CYSTIC FIBROSIS PATIENTS AND PANCREATIC INSUFFICIENCY - NDEXPERIMENTAL STUDY, RANDOMIZED, OPEN LABEL, TO EVALUATE THE EFFECT OF DOCOSAHEXAENOIC ACID (DHA) SUPPLEMENTATION VERSUS 5-METHYLTETHRAHYDROFOLATE + B12 VITAMIN AND DHA, IN CYSTIC FIBROSIS PATIENTS AND PANCREATIC INSUFFICIENCY - ND CYSTIC FIBROSIS AND PANCREATIC INSUFFICIENCY
MedDRA version: 9.1;Level: PT;Classification code 10033628
MedDRA version: 9.1;Classification code 10011762
Trade Name: PREFOLIC*30CPR GASTROR 15MG
INN or Proposed INN: Detoxifying agents for antineoplastic treatment
Trade Name: INDUSIL*OS GTT FL 30MG+FL 15ML
INN or Proposed INN: Cobamamide
AZIENDA OSPEDALIERA ISTITUTI OSPITALIERI DI VERONANULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Italy
4NCT00221546
(ClinicalTrials.gov)
September 200712/9/2005Influence of DHA-rich Supplement on DHA-status and Health Evolution of Patients With Cystic FibrosisInfluence of DHA-rich Supplement on DHA-status and Health Evolution of Patients With Cystic FibrosisCystic FibrosisDrug: Giving DHA-rich supplementUniversity Hospital, GhentBelgian Society against Cystic FibrosisCompleted6 YearsN/ABoth17Phase 2Belgium
5NCT00530244
(ClinicalTrials.gov)
March 200313/9/2007Use of Formula Fortified With DHA in Infants With Cystic FibrosisThe Effect of Formula Fortified With Docosahexaenoic Acid (DHA) on Infants With Cystic Fibrosis (CF)Cystic FibrosisDietary Supplement: Docosahexaenoic acid (DHA);Dietary Supplement: Standard formula (Enfamil)University of Massachusetts, WorcesterCystic Fibrosis FoundationCompletedN/A56 DaysAll76N/AUnited States